Continuous manufacturing has earned its moment. Regulators are behind it: the FDA and EMA adopted the ICH Q13 guideline in 2023, giving the industry a proper framework for the first time. The advantages are real too, from a smaller footprint and gentler scale-up to faster release testing. For plenty of high-volume products, it’s a genuinely good fit.
So the honest question isn’t whether continuous manufacturing works. It clearly does. The better question is narrower and more useful: for a given product, and especially for the coating step, which approach carries less risk? Look closely at the science and the regulations, and the answer is often less fashionable than the headlines suggest.
Coating uniformity is a law of averages
Start with the coating itself, because this is where the physics is unusually clear. A large body of research shows that inter-tablet coating variability falls in proportion to the square root of coating time. The longer each tablet spends passing through the spray — its dwell time in the spray zone — the more even the film, and the relationship is predictable enough to model (Chemical Engineering Science, Int. J. Pharmaceutics).
If that inverse-square-root shape feels familiar, it should. It’s the same math that governs an opinion poll, where the margin of error shrinks with the square root of the sample size. More trips through the spray zone is simply a bigger sample, and a bigger sample means a more reliable, more uniform result.
This is where batch and continuous part ways. A batch pan keeps every tablet circulating for a long stretch, so each one collects hundreds of passes through the spray. A continuous coater is engineered for speed, moving tablets through in roughly 10 to 15 minutes with far fewer passes (continuous film coating review, 2024). For a thin cosmetic coat, that’s plenty. For a functional coat, the shorter the exposure, the thinner the safety margin.
The robustness gap
That safety margin matters most when something goes slightly wrong. Suppose one spray gun begins to drift or clog. In a batch pan, the long residence time quietly absorbs it, since every tablet spends enough time circulating that the healthy guns compensate for the weak one. In a continuous coater, tablets pass through too quickly to benefit from that averaging, so a drifting nozzle can produce a run of unevenly coated tablets before the deviation is caught.
For enteric and modified-release coatings, unevenness is not a cosmetic issue. Studies show tablets with too little enteric film fail the acid-resistance test outright, while only those with sufficient film pass (enteric coating review). There is no partial credit for a coating that is almost thick enough.
“There is no partial credit for a coating that is almost thick enough.”
Where the regulations get complicated
The coating debate has a regulatory shadow, and it’s worth naming. Pharma’s entire quality system is built around the batch, a discrete and traceable quantity you can point to. A continuous line has no natural batch, so one has to be defined artificially as a slice of time or a portion of output (FDLI).
That creates real work downstream. Because material from different input lots blends together as it flows, tracing a finished tablet back to its raw materials relies on residence-time-distribution models rather than a simple lot record (residence time study, PMC). The unsettled startup period tends to produce out-of-spec material that must be identified and diverted. And if a defect surfaces, scoping the recall depends on the accuracy of those models, where a batch line would have given you a clean, obvious boundary. None of this is insurmountable, but it is more to build, validate, and defend.
First, ask what you actually want from continuous
Much of the appeal of continuous coating comes down to two goals: larger lot sizes, or the flexibility to vary lot sizes. Both are worth wanting, and both are already achievable with a modern batch coater — one built with an adequately large capacity, optimised process parameters, and interchangeable drums that give it a wide turndown ratio. That single machine can run small and large batches with equal ease, delivering the throughput and continual output you want without interrupting the manufacturing supply chain — without surrendering the batch identity that keeps traceability and recalls straightforward.
Continuous coating still has a clear sweet spot. When the goal is a very thin protective layer, just enough to harden the surface and reduce chipping in packaging, shipping, and handling, a quick pass suits the job well. But once the film has a real function to perform, the science, the robustness, and the regulations all point the same way. The right question was never continuous or batch in the abstract. It’s how much this particular coating has to do. Light and cosmetic, continuous can shine. Functional and consequential, batch remains the lower-risk path, and modern equipment means you no longer trade away throughput to take it.
The Gansons View
Continual output, without giving up the batch
Bigger lots, or the flexibility to vary them – The usual reasons to reach for a continuous coater are already within reach of a high-capacity batch coater with a wide turndown ratio. The GansCoater runs small and large batches with equal ease, delivering steady, continual output while preserving the clean batch identity that keeps traceability and recalls simple.
- Inter-tablet coating variability: tablet residence time variability (Chemical Engineering Science)
- Effect of coating time on inter- and intra-tablet coating uniformity (Int. J. Pharmaceutics)
- The current state-of-the-art in pharmaceutical continuous film coating, a review (2024)
- A review on recent advances of enteric coating (IOSR Pharmacy)
- Continuous Manufacturing in Pharma: FDA Perspective (FDLI)
- Using Residence Time Distributions to Address Traceability in Continuous Manufacturing (PMC)
